In April 2023, an artificial intelligence-powered chatbot – ChatGPT – may provide an effective way for people with cirrhosis or liver cancer to better manage their illness. This is according to a study, which tested the capabilities of ChatGPT in providing accurate answers to question regarding these two illnesses.
ChatGPT is equipped with a natural language processing tool to engage users in a more personalized conversation. It is designed to understand user inquiries and give detailed, suitable responses to questions about cirrhosis and liver cancer. For example, it can provide information on its diagnosis and treatment plans, as well as advice on lifestyle and prevention strategies.
Research has shown that ChatGPT provides correct answers to the common questions regarding cirrhosis and liver cancer. This was assessed by two human liver transplant specialists who graded the chatbot’s responses to 164 diverse questions. The results indicated that the AI tool had relatively high accuracy, answering about three-quarters of the questions correctly, and achieving a high level of accuracy for 91 questions.
Though ChatGPT does show promise, it does, however, fail to provide tailored recommendations for each user’s particular case. Nonetheless, the app is able to offer some sensible and compassionate advice to patients and caregivers regarding next steps and how to adjust to a newly-diagnosed condition.
ChatGPT is a product of Botworx AI, a company based in San Francisco, California. It was founded by Janet Tse, a software engineer with a passion for using tech to solve real-world problems. Since its establishment in 2013, Botworx AI has become a leader in developing AI-based tools for various industries, with ChatGPT being one of the company’s most popular products.
